Literature DB >> 26419799

Regional brain hypometabolism is unrelated to regional amyloid plaque burden.

Andre Altmann1, Bernard Ng1, Susan M Landau2, William J Jagust2, Michael D Greicius3.   

Abstract

In its original form, the amyloid cascade hypothesis of Alzheimer's disease holds that fibrillar deposits of amyloid are an early, driving force in pathological events leading ultimately to neuronal death. Early clinicopathological investigations highlighted a number of inconsistencies leading to an updated hypothesis in which amyloid plaques give way to amyloid oligomers as the driving force in pathogenesis. Rather than focusing on the inconsistencies, amyloid imaging studies have tended to highlight the overlap between regions that show early amyloid plaque signal on positron emission tomography and that also happen to be affected early in Alzheimer's disease. Recent imaging studies investigating the regional dependency between metabolism and amyloid plaque deposition have arrived at conflicting results, with some showing regional associations and other not. We extracted multimodal neuroimaging data from the Alzheimer's disease neuroimaging database for 227 healthy controls and 434 subjects with mild cognitive impairment. We analysed regional patterns of amyloid deposition, regional glucose metabolism and regional atrophy using florbetapir ((18)F) positron emission tomography, (18)F-fluordeoxyglucose positron emission tomography and T1-weighted magnetic resonance imaging, respectively. Specifically, we derived grey matter density and standardized uptake value ratios for both positron emission tomography tracers in 404 functionally defined regions of interest. We examined the relation between regional glucose metabolism and amyloid plaques using linear models. For each region of interest, correcting for regional grey matter density, age, education and disease status, we tested the association of regional glucose metabolism with (i) cortex-wide florbetapir uptake; (ii) regional (i.e. in the same region of interest) florbetapir uptake; and (iii) regional florbetapir uptake while correcting in addition for cortex-wide florbetapir uptake. P-values for each setting were Bonferroni corrected for 404 tests. Regions showing significant hypometabolism with increasing cortex-wide amyloid burden were classic Alzheimer's disease-related regions: the medial and lateral parietal cortices. The associations between regional amyloid burden and regional metabolism were more heterogeneous: there were significant hypometabolic effects in posterior cingulate, precuneus, and parietal regions but also significant positive associations in bilateral hippocampus and entorhinal cortex. However, after correcting for global amyloid burden, few of the negative associations remained and the number of positive associations increased. Given the wide-spread distribution of amyloid plaques, if the canonical cascade hypothesis were true, we would expect wide-spread, cortical hypometabolism. Instead, cortical hypometabolism appears to be linked to global amyloid burden. Thus we conclude that regional fibrillar amyloid deposition has little to no association with regional hypometabolism.
© The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Alzheimer’s disease; amyloid imaging; glucose metabolism; positron emission tomography

Mesh:

Substances:

Year:  2015        PMID: 26419799      PMCID: PMC4806718          DOI: 10.1093/brain/awv278

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  61 in total

Review 1.  Alzheimer's disease: the amyloid cascade hypothesis.

Authors:  J A Hardy; G A Higgins
Journal:  Science       Date:  1992-04-10       Impact factor: 47.728

2.  Longitudinal assessment of Aβ and cognition in aging and Alzheimer disease.

Authors:  Victor L Villemagne; Kerryn E Pike; Gaël Chételat; Kathryn A Ellis; Rachel S Mulligan; Pierrick Bourgeat; Uwe Ackermann; Gareth Jones; Cassandra Szoeke; Olivier Salvado; Ralph Martins; Graeme O'Keefe; Chester A Mathis; William E Klunk; David Ames; Colin L Masters; Christopher C Rowe
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  In vivo tau imaging: obstacles and progress.

Authors:  Victor L Villemagne; Nobuyuki Okamura
Journal:  Alzheimers Dement       Date:  2014-06       Impact factor: 21.566

4.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

5.  The impact of different presenilin 1 andpresenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors.

Authors:  T Gómez-Isla; W B Growdon; M J McNamara; D Nochlin; T D Bird; J C Arango; F Lopera; K S Kosik; P L Lantos; N J Cairns; B T Hyman
Journal:  Brain       Date:  1999-09       Impact factor: 13.501

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

Review 7.  The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics.

Authors:  John Hardy; Dennis J Selkoe
Journal:  Science       Date:  2002-07-19       Impact factor: 47.728

8.  Amyloid deposition is associated with impaired default network function in older persons without dementia.

Authors:  Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson
Journal:  Neuron       Date:  2009-07-30       Impact factor: 17.173

9.  Age-specific population frequencies of cerebral β-amyloidosis and neurodegeneration among people with normal cognitive function aged 50-89 years: a cross-sectional study.

Authors:  Clifford R Jack; Heather J Wiste; Stephen D Weigand; Walter A Rocca; David S Knopman; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Gregory M Preboske; Vernon S Pankratz; Prashanthi Vemuri; Ronald C Petersen
Journal:  Lancet Neurol       Date:  2014-09-04       Impact factor: 44.182

10.  Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.

Authors:  Yi Li; Juha O Rinne; Lisa Mosconi; Elizabeth Pirraglia; Henry Rusinek; Susan DeSanti; Nina Kemppainen; Kjell Någren; Byeong-Chae Kim; Wai Tsui; Mony J de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-06-20       Impact factor: 9.236

View more
  48 in total

1.  Coupled Imaging with [18F]FBB and [18F]FDG in AD Subjects Show a Selective Association Between Amyloid Burden and Cortical Dysfunction in the Brain.

Authors:  Agostino Chiaravalloti; Anna Elisa Castellano; Maria Ricci; Gaetano Barbagallo; Pasqualina Sannino; Francesco Ursini; Georgios Karalis; Orazio Schillaci
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

2.  Mnemonic Training Reshapes Brain Networks to Support Superior Memory.

Authors:  Martin Dresler; William R Shirer; Boris N Konrad; Nils C J Müller; Isabella C Wagner; Guillén Fernández; Michael Czisch; Michael D Greicius
Journal:  Neuron       Date:  2017-03-08       Impact factor: 17.173

Review 3.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies.

Authors:  Justin M Long; David M Holtzman
Journal:  Cell       Date:  2019-09-26       Impact factor: 41.582

Review 4.  Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials.

Authors:  Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2017-03-22       Impact factor: 21.566

Review 5.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

Review 6.  Stroke in CNS white matter: Models and mechanisms.

Authors:  Miguel Alejandro Marin; S Thomas Carmichael
Journal:  Neurosci Lett       Date:  2018-08-08       Impact factor: 3.046

7.  Associating Multi-Modal Brain Imaging Phenotypes and Genetic Risk Factors via a Dirty Multi-Task Learning Method.

Authors:  Lei Du; Fang Liu; Kefei Liu; Xiaohui Yao; Shannon L Risacher; Junwei Han; Andrew J Saykin; Li Shen
Journal:  IEEE Trans Med Imaging       Date:  2020-10-28       Impact factor: 10.048

8.  Relationships Between Tau and Glucose Metabolism Reflect Alzheimer's Disease Pathology in Cognitively Normal Older Adults.

Authors:  Jenna N Adams; Samuel N Lockhart; Lexin Li; William J Jagust
Journal:  Cereb Cortex       Date:  2019-05-01       Impact factor: 5.357

9.  Divergent regional patterns of cerebral hypoperfusion and gray matter atrophy in mild cognitive impairment patients.

Authors:  Miranka Wirth; Alexa Pichet Binette; Peter Brunecker; Theresa Köbe; A Veronica Witte; Agnes Flöel
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

Review 10.  ApoE and cerebral insulin: Trafficking, receptors, and resistance.

Authors:  Elizabeth M Rhea; Jacob Raber; William A Banks
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.